Rocket Pharmaceuticals, Inc.
RCKT
$2.93
-$0.14-4.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 108.26M | 101.96M | 95.16M | 86.64M | 76.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 270.22M | 273.21M | 270.79M | 266.80M | 261.84M |
| Operating Income | -270.22M | -273.21M | -270.79M | -266.80M | -261.84M |
| Income Before Tax | -258.03M | -258.75M | -258.08M | -253.26M | -249.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -258.03 | -258.75 | -258.08 | -253.26 | -249.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -258.03M | -258.75M | -258.08M | -253.26M | -249.31M |
| EBIT | -270.22M | -273.21M | -270.79M | -266.80M | -261.84M |
| EBITDA | -260.11M | -263.83M | -261.84M | -258.48M | -254.16M |
| EPS Basic | -2.63 | -2.73 | -2.75 | -2.79 | -2.87 |
| Normalized Basic EPS | -1.69 | -1.76 | -1.77 | -1.80 | -1.85 |
| EPS Diluted | -2.63 | -2.73 | -2.75 | -2.79 | -2.87 |
| Normalized Diluted EPS | -1.69 | -1.76 | -1.77 | -1.80 | -1.85 |
| Average Basic Shares Outstanding | 395.53M | 378.98M | 374.79M | 363.27M | 349.99M |
| Average Diluted Shares Outstanding | 395.53M | 378.98M | 374.79M | 363.27M | 349.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |